<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04719013</url>
  </required_header>
  <id_info>
    <org_study_id>DO609886A</org_study_id>
    <nct_id>NCT04719013</nct_id>
  </id_info>
  <brief_title>Treatment With the Evoke System for Facial and Submental Laxity</brief_title>
  <official_title>Treatment With the Evoke System for Facial and Submental Laxity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InMode MD Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InMode MD Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the efficacy, patient comfort, and patient satisfaction&#xD;
      after Evoke treatment for face and submental area&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to evaluate the efficacy, patient comfort, and patient satisfaction&#xD;
      after Evoke treatment for face and submental area Prospective, open label clinical study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate change in skin appearance</measure>
    <time_frame>Day 0, Month 6</time_frame>
    <description>Evaluate change in skin appearance comparing pre and 6 months post last treatment photographs (as assessed by blinded investigators)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate change in skin appearance using 3D Photographic analysis</measure>
    <time_frame>Day 0, month 6</time_frame>
    <description>Evaluate change in skin appearance using 3D Photographic analysis at 6 months follow up visit compared to the baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate Investigator assessment of the skin appearance</measure>
    <time_frame>Day 0, month 6</time_frame>
    <description>Evaluate Investigator assessment of the skin appearance improvement comparing pre and post treatment using 0 - 4 -points Likert scale at 6 months follow up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Subject assessment of improvement and satisfaction</measure>
    <time_frame>month 6</time_frame>
    <description>Evaluate Subject assessment of improvement and satisfaction using 0 - 4 -points Likert scale at 6 months follow up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological Analysis - Collagen (up to 5 subjects)</measure>
    <time_frame>Day 0, month 3</time_frame>
    <description>Relative changes in protein abundance in biopsies taken at post treatment compare to control will be quantified using an image processing software based on fluorescence signal intensity. The change from baseline will be calculated at 3M time frame.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Laxity; Skin</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evoke radiofrequency device</intervention_name>
    <description>Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments,</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Signed informed consent to participate in the study.&#xD;
&#xD;
          -  Female and male subjects, 35 and 75 years of age at the time of enrolment&#xD;
&#xD;
          -  If female, not pregnant, lactating and must be either post-menopausal, surgically&#xD;
             sterilized, or using a medically acceptable form of birth control at least 3 months&#xD;
             prior to enrolment (i.e., oral contraceptives, contraceptive implant, barrier methods&#xD;
             with spermicide or abstinence).&#xD;
&#xD;
          -  In addition, negative urine pregnancy test as tested before each treatment and at the&#xD;
             last visit for women with childbearing potential (e.g. not menopause).&#xD;
&#xD;
          -  General good health confirmed by medical history and skin examination of the treated&#xD;
             area.&#xD;
&#xD;
          -  Willing to have photographs and images taken of the treated areas to be used&#xD;
             de-identified in evaluations, publications and presentations.&#xD;
&#xD;
          -  The patients should be willing to comply with the study procedure and schedule,&#xD;
             including the follow up visit, and will refrain from using any other aesthetic&#xD;
             treatment methods for the last 6 months and during the entire study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Pacemaker or internal defibrillator, or any other active electrical implant anywhere&#xD;
             in the body.&#xD;
&#xD;
          -  Permanent implant in the treated area such as metal plates and screws, silicone&#xD;
             implants or an injected chemical substance, unless deep enough in the periostal plane.&#xD;
&#xD;
          -  Current or history of skin cancer, or current condition of any other type of cancer,&#xD;
             or premalignant moles.&#xD;
&#xD;
          -  Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled&#xD;
             hypertension, and liver or kidney diseases.&#xD;
&#xD;
          -  Pregnancy and nursing.&#xD;
&#xD;
          -  Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use&#xD;
             of immunosuppressive medications.&#xD;
&#xD;
          -  Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex&#xD;
             in the treatment area, may be treated only following a prophylactic regimen.&#xD;
&#xD;
          -  Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction.&#xD;
&#xD;
          -  Any active condition in the treatment area, such as sores, psoriasis, eczema, and&#xD;
             rash.&#xD;
&#xD;
          -  History of skin disorders, keloids, abnormal wound healing, as well as very dry and&#xD;
             fragile skin.&#xD;
&#xD;
          -  History of bleeding coagulopathies or use of anticoagulants in the last 10 days.&#xD;
&#xD;
          -  Any surgery in treated area within 3 months prior to treatment.&#xD;
&#xD;
          -  Six months delay is required if other recent treatments like light, CO2 laser or RF&#xD;
             were performed on the same area.&#xD;
&#xD;
          -  Use of Isotretinoin (AccutaneÂ®) within 6 months prior to treatment.&#xD;
&#xD;
          -  Simultaneously participating in another investigator drug or device study or has&#xD;
             completed the follow-up phase for the primary endpoint of any previous study less than&#xD;
             1 year prior to the first evaluation in this study.&#xD;
&#xD;
          -  As per the practitioner's discretion, refrain from treating any condition that might&#xD;
             make it unsafe for the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Medical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AboutSkin dermatology</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lupo Center for Aesthetic and General Dermatology</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Plastic Surgery Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Refresh dermatology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cutis Laxa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

